MedWatch

US Democrats fighting insulin prices might falter as midterms near

The upcoming midterm elections in the US could throw a wrench into Democrats’ plans to cap diabetes patients’ out-of-pocket insulin expenses.

Photo: George Frey/Reuters/Ritzau Scanpix

Bipartisan support is needed before the US can secure more affordable insulin for diabetes patients, and bipartisan support is becoming more unlikely as November’s midterm elections in the US come closer, reports Reuters.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs